Condition: Malignancy · Non-hodgkin Lymphoma · Multiple Myeloma · Sponsor: Cyteir Therapeutics, Inc.
This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| University of California San Francisco | San Francisco, California, United States | — |
| Stanford Comprehensive Cancer Center | Stanford, California, United States | — |
| Sarah Cannon Research Institute at HealthONE | Denver, Colorado, United States | — |
| Florida Cancer Specialists and Research Institute | Sarasota, Florida, United States | — |
| Massachusetts General Hospital | Boston, Massachusetts, United States | — |
| Dana Farber Cancer Institute | Boston, Massachusetts, United States | — |
| University of Michigan | Ann Arbor, Michigan, United States | — |
| Mayo Clinic | Rochester, Minnesota, United States | — |
| John Theurer Cancer Center at HUMC | Hackensack, New Jersey, United States | — |
| NYU Langone Health | New York, New York, United States | — |
| Oklahoma University-Stephenson Cancer Center | Oklahoma City, Oklahoma, United States | — |
| Thomas Jefferson University, Sidney Kimmel Cancer Center | Philadelphia, Pennsylvania, United States | — |
+ 4 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03997968